Aluminum Oxide
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Aluminum Oxide: From No Labeled Indication to Rheumatoid Arthritis
One-Sentence Summary
Aluminum oxide (alumina) has no approved indication in the available US regulatory data. It is marketed in pellet-form “Alumina” products. The TxGNN model predicts it may be effective for Rheumatoid Arthritis with a very high score, but the 1 registered clinical trial is an unrelated hip-implant device study, and none of the 20 publications tests alumina as a treatment for the disease. This is a model-only prediction with no supporting clinical evidence.
Quick Overview
| Item | Content |
|---|---|
| Predicted New Indication | Rheumatoid arthritis |
| TxGNN Prediction Score | 99.98% |
| Evidence Level | L5 (model prediction only) |
| US Market Status | ✓ Marketed |
| Number of NDAs | 20 listings (no application numbers provided) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Aluminum oxide is an inert ceramic material, an adsorbent and a vaccine adjuvant. It has no known anti-inflammatory or DMARD-like activity, so no credible therapeutic mechanism for rheumatoid arthritis can be identified.
The very high TxGNN score (99.98%) comes from the knowledge graph alone. The papers linked to this prediction fall into three groups: nanocarrier studies where the material is only a delivery scaffold, diagnostic assays that use kaolin or bentonite as reagents, and joint-implant studies where alumina is the bearing material. None of them treats rheumatoid arthritis with alumina.
The other nine top-ranked predictions (for example brachydactyly-syndactyly syndrome, heparin cofactor 2 deficiency and thrombotic disease) also lack clinical support.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00764530 | Not applicable (device) | Completed | 342 | Ceramic-on-ceramic total hip system with an alumina insert and head. It tests implant safety and performance, not rheumatoid arthritis treatment (relevance grade C). |
Literature Evidence
No RCTs were found. The table lists the most relevant items, ordered roughly by closeness to the topic.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 12211691 | 2002 | In vitro | J Bone Joint Surg Br | Alumina and zirconia particles were tested on synoviocytes from osteoarthritis and RA patients for IL-1, IL-6 and arachidonic acid metabolism. This is a biomaterial safety model, not a treatment study, and the abstract indicates no significant effect. |
| 2838005 | 1988 | Review | Arch Pathol Lab Med | Silica-related disease review that lists rheumatoid arthritis as a possible complication of exposure. This suggests risk, not benefit. |
| 30062938 | 2018 | Clinical study | Bone Joint J | Mid-term outcomes of alumina ceramic elbow replacement in RA patients. The alumina is an implant material, not a drug. |
| 28238009 | 2017 | Case series | Acta Med Okayama | Long-term results of cementless alumina ceramic elbow replacement in 17 RA patients. This is again about implants. |
| 16882533 | 2006 | Case-control | Environ Health Perspect | Asbestos exposure and autoimmune disease risk in Libby, Montana. It is unrelated to alumina treatment. |
| 35549591 | 2022 | Preclinical | J Drug Target | ZIF-8 nanoparticles for targeted dexamethasone delivery to arthritic joints. The active drug is dexamethasone, not alumina. |
| 35819069 | 2022 | Preclinical | ACS Biomater Sci Eng | CeO2-ZIF-8 nanocomposite for photothermal and ROS-scavenging RA therapy. It does not involve alumina. |
| 22193222 | 2012 | Animal study | Rheumatol Int | Kaolin/carrageenan-induced arthritis was more severe in older rats. Kaolin is used here to induce arthritis, not to treat it. |
| 32707885 | 2020 | Preclinical | Molecules | A benzylideneacetophenone derivative was tested in a kaolin/carrageenan arthritis rat model. Kaolin is only the inducing agent. |
| 32342135 | 2020 | Preclinical | Naunyn Schmiedebergs Arch Pharmacol | Malva parviflora extract was tested in a kaolin/carrageenan mono-arthritis mouse model. It is unrelated to alumina therapy. |
US Market Information
The 20 listings appear to be “Alumina” pellet products from homeopathic-style manufacturers (Boiron and Hahnemann Laboratories). The source data gives no license numbers or approved indication text. The first 5 listings are shown.
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| Not provided | Alumina (Boiron) | Pellet | Not stated |
| Not provided | Alumina (Hahnemann Laboratories, Inc.) | Pellet | Not stated |
| Not provided | Alumina (Hahnemann Laboratories, Inc.) | Pellet | Not stated |
| Not provided | Alumina (Boiron) | Pellet | Not stated |
| Not provided | Alumina (Hahnemann Laboratories, Inc.) | Pellet | Not stated |
Other dosage forms in the data are globules and liquids.
Safety Considerations
Please refer to the package insert for safety information.
No drug interactions were found in the queried data.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on the knowledge graph alone. The one registered trial is an implant device study, and the literature contains no test of alumina as a rheumatoid arthritis therapy. No plausible mechanism exists, and the safety data required for screening is missing.
To proceed, the following is needed:
- FDA package insert warnings and contraindications (blocking gap; safety screening cannot start without them)
- Mechanism of action data from DrugBank
- A plausible anti-inflammatory or immunomodulatory mechanism for alumina, backed by preclinical evidence
- Confirmation of whether the marketed products carry any labeled indication
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.